Drug combination studies and their synergy quantification using the chou-talalay method-letter

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2400-

  Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; DRUG;

ACCESS TO INFORMATION; ALGORITHM; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CHOU TALALAY METHOD; CLINICAL PHARMACOLOGY; DRUG ANTAGONISM; DRUG TARGETING; HUMAN; INTERMETHOD COMPARISON; LOGLINEAR MODEL; NONLINEAR SYSTEM; PRIORITY JOURNAL; REPRODUCIBILITY; SCATCHARD PLOT; SHORT SURVEY; STATISTICAL DISTRIBUTION; VALIDATION PROCESS; ANIMAL; DRUG COMBINATION; DRUG POTENTIATION; PROCEDURES;

ALGORITHMS; ANIMALS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84938118625     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3763     Document Type: Short Survey

References (5)

1. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2013;2:e00747.
2. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
3. Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014;20:1027-34.
4. Boik JC, Newman RA, Boik RJ. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat Med 2008;27:1040-61.
5. Journals unite for reproducibility. Nature 2014;515:7 (Editorial).